Atlas Trials

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Clinical trial NCT04879628 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04879628
Sponsor
Sanofi
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Sclerosis
Start date
2021-06-07
Primary completion
2022-09-21
Enrollment
129

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.